Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.

NCT01612676 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT01612676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01612676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.
Lead sponsor
Ferring Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
November 30, 2013
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock